PA-GCCA
The Clean Energy Ministerial CCUS (CEM CCUS) and the Global Cement and Concrete Association (GCCA) have today, at the first-ever Global Clean Energy Action Forum (GCEAF), announced an agreement that will help scale up the deployment of carbon capture, utilisation and storage (CCUS) throughout the cement and concrete industry, in a move to stimulate innovation, investment and increase the pace of decarbonisation efforts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220923005359/en/
Major CCUS industry and government collaboration announced at Global Clean Energy Action Forum (GCEAF) in Pittsburgh, USA. Left to right: Thomas Guillot, CEO of the Global Cement and Concrete Association, Henriette Nesheim, Assistant Director General, Norwegian Ministry of Petroleum and Energy – and CEM CCUS Initiative Co-Lead from Norway, Brad Crabtree, Assistant Secretary, Fossil Energy and Carbon Management, US Department of Energy (Photo: Business Wire)
Central to the agreement will be exploring incentives, policy frameworks and finance solutions at a global level that can enable industrial-scale CCUS projects over the next ten years. The two organisations will work together to ensure the long-term deployment of CCUS, beyond 2030, via both policy and technological development.
The agreement sets out the role CCUS can have in safely and effectively delivering a net zero future and facilitates the identification and mapping of potential cement-sector CCUS projects. It will explore the transport and storage infrastructure needs involved in integrating cement CCUS projects into strategic CCUS transport and storage hubs. It will also help to foster project partnerships and lead to acceleration of projects in developing economies.
Thomas Guillot, CEO of the Global Cement and Concrete Association, said: “Cement is the vital ingredient in concrete, the world’s most-used human-made material. It is the backbone of the modern world. The industry is striving to innovate at every stage of the concrete life cycle. We see carbon capture as a vital lever for the global cement industry to achieve its ambitious goal of net-zero concrete by 2050.
“We are starting to see the first CCUS projects already emerge. We have mapped 35 projects announced and underway across the world and up to 100 additional projects are also in the pipeline among our member companies who operate all around the globe.”
Mr Guillot added: “This is good progress, but we cannot achieve our decarbonisation mission alone. CCUS is a key enabling technology, and it is a critical area for collaboration to ensure that government policy, enabling infrastructure and wider investment is in place. That is why the partnership with the Clean Energy Ministerial CCUS Initiative is so important, to help unlock and accelerate further progress and deployment.”
Henriette Nesheim, Assistant Director General, Norwegian Ministry of Petroleum and Energy – and CEM CCUS Initiative Co-Lead from Norway, said: “This is a great opportunity to work together with a vitally important industry. In Norway we are already building our first cement-CCS project in Brevik, and we look forward to sharing the experience with others.”
Brad Crabtree, Assistant Secretary, Fossil Energy and Carbon Management, US Department of Energy, said: “Reaching our ambitious climate goals requires the decarbonization of various heavy industries, including cement production. In the United States, through the support of Congress, we are currently funding projects to develop carbon capture technologies in cement and other key industrial sectors that are essential to modern life, with the aim of helping to achieve net-zero emissions economywide by 2050 and retaining and creating high-wage industrial jobs. The U.S. Government is keen to drive progress in this area, together with our partners in the CEM CCUS Initiative and the Global Cement and Concrete Association.”
To reach these objectives, both parties have agreed to the organisation of expert workshops, inclusive of CEM CCUS and GCCA members, as well as relevant stakeholders and partners including the CEM Industry Deep Decarbonisation Initiative (IDDI). Both parties will also produce joint reports and organise public events outlining progress in opportunities to implement CCUS projects at strategic hubs.
The agreement was announced at a GCCA and CEM CCUS led event at the Global Energy Action Forum, focused on the challenge and opportunity for CCUS as a major decarbonisation lever for the global cement and concrete sector. This aligns with a core pillar of the GCCA’s 2050 Net Zero Roadmap, launched last year, in which its members have committed to the deployment of at least ten industrial-scale CCUS projects by 2030.
At the event, the industry summarised the key challenges in accelerating the deployment of CCUS and outlined the enabling factors crucial to increasing its rollout to create a greener concrete future. These factors include supporting policies and financing, public procurement progress and CO2 infrastructure and storage options alongside strategic hubs.
-ends-
Notes to editors:
Speakers at the GCCA and CEM CCUS led event at the Global Energy Action Forum included:
- Henriette Nesheim, Assistant Director General, Norwegian Ministry of Petroleum and Energy – and CEM CCUS Initiative Co-Lead from Norway
- Dan Dorner, Head of CEM Secretariat
- Thomas Guillot, CEO, Global Cement and Concrete Association
Panel:
- Chris Ward, CEO, Lehigh Hanson Cement
- Bjorn Otto Sverdrup, ExCom Chair, OGCI
- Tareq Emtairah, Director, UNIDO
- Brad Crabtree, Assistant Secretary, Fossil Energy and Carbon Management, US Department of Energy
- Khalid Abuleif, Chief Climate Negotiator, Saudi Arabia
- Moderator: Juho Lipponen, CEM CCUS
About the GCCA
Launched in January 2018, the Global Cement and Concrete Association (GCCA) is dedicated to developing and strengthening the sector’s contribution to sustainable construction. The GCCA aims to foster innovation throughout the construction value chain in collaboration with industry associations as well as architects, engineers, and innovators. The association demonstrates how concrete solutions can meet global construction challenges and sustainable development goals while showcasing responsible industrial leadership in the manufacture and use of cement and concrete. It complements and supports the work of associations at national and regional levels.
About CEM CCUS
The Clean Energy Ministerial CCUS Initiative is a group of 14 member countries who have joined forces to accelerate CCUS together. The CEM CCUS countries all develop comprehensive CCUS programmes, with the intent to decarbonise all relevant industrial sectors. The objective of the Initiative is to accelerate CCUS as a viable CO2 mitigation option, facilitate diffusions of knowledge on technologies, regulations, and policies, and lead to strategic partnerships to accelerate both near- and longer-term investment in CCUS. As an action-orientate platform, the Imitative does not perform analysis, but serves to bring government, industry and the financial and investment sectors together.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220923005359/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
